Waheed Dur-E-Nayab, Burdier F Ricardo, Eklund Carina, Baussano Iacopo, Mariz Filipe Colaço, Téblick Laura, Mugo Nelly, Watson-Jones Deborah, Stanley Margaret, Baay Marc, Vorsters Alex
Centre for Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Belgium.
Karolinska Institutet, Department of Laboratory Medicine, Huddinge, Sweden.
Prev Med Rep. 2023 Aug 14;35:102368. doi: 10.1016/j.pmedr.2023.102368. eCollection 2023 Oct.
The 12th HPV Prevention and Control meeting was held on June 2-3, 2022, in Antwerp, Belgium. This technical meeting focused on several topics. This report summarises the discussions and lessons learned on two topics: an update on one-dose HPV vaccination studies and humoral immune responses upon HPV vaccination. Long-term follow-up studies from Costa Rica (eleven years) and India (ten years) report stable levels of antibodies after a single HPV vaccination. High vaccine effectiveness against incident persistent HPV 16/18 infection was seen in India (95.4%, 85.0-99.9) ten years postvaccination and in Kenya (97.5%, 81.7-99.7) eighteen months postvaccination, an important observation in a setting with a higher HPV prevalence. The potential impact of HPV vaccination using a one-dose schedule in India was modelled and showed that implementation of one-dose schedule can contribute towards achieving WHO Cervical Cancer elimination goals. These data support the WHO SAGE recommendations for adopting a one-dose schedule for females aged 9-20 years. Immunobridging studies were discussed during the meeting. General agreement was reached that when thoughtfully applied, they can support and accelerate the expanded use of HPV vaccine with new vaccine schedules, age cohorts, or vaccine formulations. Internationally standardised measurements of HPV immune responses important for the progress of HPV vaccinology field. Humoral immune responses upon HPV vaccination plateau at 24 months regardless of number of doses, therefore, data should be analysed after at least 24 months of follow-up to bridge studies accurately.
第12届人乳头瘤病毒（HPV）防控会议于2022年6月2日至3日在比利时安特卫普举行。本次技术会议聚焦多个主题。本报告总结了关于两个主题的讨论内容和经验教训：一剂次HPV疫苗接种研究的最新进展以及HPV疫苗接种后的体液免疫反应。来自哥斯达黎加（11年）和印度（10年）的长期随访研究报告称，单次HPV疫苗接种后抗体水平稳定。在印度，接种疫苗10年后对新发持续性HPV 16/18感染的疫苗效力较高（95.4%，85.0 - 99.9）；在肯尼亚，接种疫苗18个月后疫苗效力也较高（97.5%，81.7 - 99.7），这在HPV流行率较高的环境中是一项重要观察结果。对印度采用一剂次HPV疫苗接种方案的潜在影响进行了建模，结果表明实施一剂次方案有助于实现世界卫生组织消除宫颈癌的目标。这些数据支持世界卫生组织免疫战略咨询专家组（SAGE）关于对9至20岁女性采用一剂次接种方案的建议。会议期间讨论了免疫桥接研究。与会者普遍达成共识，即若审慎应用，免疫桥接研究可支持并加速HPV疫苗在新的接种程序、年龄队列或疫苗剂型方面的扩大使用。HPV免疫反应的国际标准化测量对HPV疫苗学领域的发展至关重要。无论接种剂次数多少，HPV疫苗接种后的体液免疫反应在24个月时达到平台期，因此，应在至少24个月的随访后分析数据，以便准确进行桥接研究。
